
Many of the available disability outcome measures used in clinical trials of multiple sclerosis are insensitive to change over time, zzso zzso or insensitive to zzso health status or quality of zzso zzso focus on therapies that slow or reverse disability progression makes it essential to refine existing measures or to develop new zzso Major changes to the expanded disability status scale should be avoided to prevent the loss of acceptance by regulators as a measure for primary outcomes in trials that provide substantial evidence of zzso Rather, we recommend practical zzso zzso although substantial data support the multiple sclerosis functional composite as an alternative measure, changes to its component tests and scoring method are zzso Novel approaches, including the use of composite zzso zzso zzso and measurement of zzso show promise as zzso to the current disability measures, but are insufficiently validated to serve as zzso A collaborative approach that involves academic experts, regulators, industry zzso and funding agencies is needed to most effectively develop disability outcome zzso 

